SIMCERE PHARMAC. GRP LTD - Asset Resilience Ratio
SIMCERE PHARMAC. GRP LTD (S2P) has an Asset Resilience Ratio of 0.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SIMCERE PHARMAC. GRP LTD working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SIMCERE PHARMAC. GRP LTD's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SIMCERE PHARMAC. GRP LTD total assets.
Liquid Assets Composition Over Time
This chart breaks down SIMCERE PHARMAC. GRP LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read S2P liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €65.53 Million | 0.44% |
| Total Liquid Assets | €65.53 Million | 0.44% |
Asset Resilience Insights
- Limited Liquidity: SIMCERE PHARMAC. GRP LTD maintains only 0.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SIMCERE PHARMAC. GRP LTD Industry Peers by Asset Resilience Ratio
Compare SIMCERE PHARMAC. GRP LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Dr. Reddy's Laboratories Limited
F:RDDA |
Drug Manufacturers - Specialty & Generic | 11.36% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 0.66% |
Annual Asset Resilience Ratio for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SIMCERE PHARMAC. GRP LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.44% | €65.53 Million ≈ $76.61 Million |
€14.73 Billion ≈ $17.22 Billion |
+0.36pp |
| 2024-12-31 | 0.09% | €10.00 Million ≈ $11.69 Million |
€11.51 Billion ≈ $13.46 Billion |
-0.02pp |
| 2023-12-31 | 0.10% | €11.14 Million ≈ $13.02 Million |
€10.85 Billion ≈ $12.69 Billion |
-8.83pp |
| 2022-12-31 | 8.94% | €964.23 Million ≈ $1.13 Billion |
€10.79 Billion ≈ $12.61 Billion |
-2.97pp |
| 2021-12-31 | 11.91% | €1.21 Billion ≈ $1.41 Billion |
€10.16 Billion ≈ $11.88 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more